Navigation Links
New Bone Drug May Prevent Fractures But Raise Clot Risk
Date:2/24/2010

It's too soon to say if it outperforms existing drugs, expert says

WEDNESDAY, Feb. 24 (HealthDay News) -- A new drug to fight osteoporosis, the bone condition associated with aging and debilitating fractures, reduces the risk of fractures and the risk of some breast cancers, heart disease and stroke, according to a new study.

But, like other anti-osteoporosis drugs already on the market, the drug -- called lasofoxifene -- also boosts the risk of blood clots, the researchers found. Lasofoxifene, proposed brand name Fablyn, is not yet approved by the U.S. Food and Drug Administration.

Overall, lasofoxifene looks good, according to lead study author Dr. Steven Cummings, professor and director of the San Francisco Coordinating Center at the University of California San Francisco.

But Dr. Carolyn Becker, who wrote an editorial accompanying the study published in the Feb. 25 issue of the New England Journal of Medicine, is taking a wait-and-see approach. "It may turn out to be a dynamite drug, but it's not anything I would rush in to use as a clinician," she said. "There are too many unknowns."

For the study, Cummings and his team assigned 8,556 women who were aged 59 to 80 and had osteoporosis to take a daily dose of the drug (either 0.25 or 0.5 milligrams a day) or a placebo for five years. All had a bone mineral density T score of minus 2.5, considered osteoporosis.

The new drug is in a class of medications known as selective estrogen-receptor modulators (SERM), which act like estrogen in some tissues but anti-estrogen in other. "They act like estrogens when binding to bone cells and don't act like estrogen in the breast [thus not 'feeding' any cancers of the breast]," Cummings said.

Another SERM, already on the market, is raloxifene (Evista).

In the study, the researchers found that lasofoxifene "reduces the risk of all fractures (spinal and elsewhere), breast cancer, heart disease and stroke," Cummings said. "Breast cancer by more than half, nonspinal fractures by about a quarter, which is similar to what other drugs have done, stroke and heart disease by a quarter to a third."

The results he cites are all for the higher dose, 0.5 milligrams a day, when compared to placebo. The higher dose worked better, they found, and is the dose planned for clinical use.

When Cummings looked at adverse events during the follow-up, he found deaths were comparable in the high-dose and placebo group (73 and 65), but more deaths occurred in the low-dose group (90) from any cause.

More women taking the drug developed lung cancer, too -- 28 compared to four in the placebo group. Cummings said that may be related to chance.

Blood clot risk more than doubled on the drug, they found, a risk similar to what is found with estrogen and other SERMs, although the absolute risk was still small.

"The big news for osteoporosis is that lasofoxifene also prevents the fractures that cause most of the disability," Cummings said, referring to non-spinal fractures such as hip, upper arm and pelvis.

But Becker pointed out in her editorial that this effect did not kick in until five years, and the absolute risk reductions were small.

Women with osteoporosis should first consider drugs known as bisphosphonates (Fosamax and others), Cummings said, turning to SERM drugs if they are considered at higher risk.

Cummings has reported receiving consulting fees from pharmaceutical companies including Pfizer, which is developing Fablyn. Becker reports no disclosures.

More information

To learn more about medications for osteoporosis, visit the National Osteoporosis Foundation.



SOURCES: Steven R. Cummings, M.D., professor, director, San Francisco Coordinating Center, University of California, San Francisco; Carolyn Becker, M.D., associate professor, medicine, Harvard Medical School and Brigham and Women's Hospital, Boston; Feb. 25, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Psychiatrys main method to prevent mistaken diagnoses of depression doesnt work: NYU study
2. Bitrex Bitter Safety Additive Exhibiting at the Safe Kids Fair 2010; Making a Bitter Face to Learn about Poisoning Prevention
3. AT&T Foundations $50,000 Donation to National Health Foundation Supports Teen Pregnancy Prevention Program
4. African-Americans attitudes about lung cancer may hinder prevention
5. Sacred Heart Medical Center Cited for Violation of Safety Standards in H1N1 Prevention
6. New Safety Bath and Sill Mats Help Prevent Slip and Fall in Bathrooms - from Martinson-Nicholls
7. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
8. VIDEO from Medialink and AAFA: Asthma PSA Reinforces Prevention of Asthma Symptoms
9. Medical Nurse Training, Inc. Partners With Healthcare Companies to Develop Corporate Branded, Accredited Programs for Patient/Bed Safety and Fall Prevention/Protection
10. Botox May Prevent Some Migraines
11. Pet Dental Month Prime Time To Schedule Preventive Annual Cleaning For Pets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... , ... February 13, 2016 , ... Many individuals looking ... protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved into ... once more, but without the high-carb repercussions. IsoPasta has 30 grams of protein ...
(Date:2/13/2016)... ... 2016 , ... When an Au Pair comes all the way around the world ... for and they are often worried things won’t go well. More often than not, however, ... Au Pair of the Year winner’s all commented how their Au Pairs have become a ...
(Date:2/12/2016)... LA (PRWEB) , ... February 12, 2016 , ... The ... St. Landry and Evangeline Parishes. The purpose of these scholarships is to encourage ... encourage those individuals to seek employment within these two parishes. , “We have ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical ... in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the ... products in action, learn more about their chosen field and network with their colleagues. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a leader in cloud ... Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. ... their small and medium business (SMB) clients. , In recent years, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... SAN DIEGO and SEOUL, ... -- Silicon Biosys­tems Menarini and Macrogen, Inc. today ... clinical assays and innovative procedures for precision medicine ... to combine Silicon Biosystems, DEPArray™ digital-sorting technology with ... development of tests certified under the Clinical Laboratory ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
Breaking Medicine Technology: